Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
AIM Vaccine Co., Ltd. Class H ( (HK:6660) ) has provided an announcement.
AIM Vaccine Co., Ltd. has received approval for clinical trials of its mRNA herpes zoster vaccine in both China and the U.S., showcasing the strength of its mRNA technology platform. The vaccine demonstrated significantly higher immunity levels compared to international benchmarks in preclinical tests, and with no mRNA herpes zoster vaccine currently approved globally, AIM’s product could reshape the market landscape. The market for herpes zoster vaccines is expected to grow significantly, and upon marketing approval, AIM’s vaccine is anticipated to contribute substantially to the company’s growth.
More about AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. is a leading enterprise in the development of mRNA vaccine products in China. The company has an independent patent for mRNA technology and a mature research and development system for mRNA vaccines. It focuses on the industrialization and commercialization of mRNA vaccine products, aiming to address unmet clinical needs and enhance its innovation capabilities and competitiveness.
Average Trading Volume: 4,588,731
Technical Sentiment Signal: Sell
Find detailed analytics on 6660 stock on TipRanks’ Stock Analysis page.